Research on viral diseases and the response to them. Covers Ebola and mpox, diagnostics, post-viral fatigue, and outbreak control strategies.
The current Ebola outbreak in West Africa requires a rapid global response to contain the virus, which has already killed nearly 2000 people and may infect up to 20,000. Experts warn that fear, mistrust, and lack of resources are exacerbating the situation.
Researchers found that viruses can contaminate surfaces within 2-4 hours, spreading to 40-60% of workers and visitors. Disinfecting wipes with quaternary ammonium compounds (QUATS) reduced virus spread by 80-99% when used in conjunction with hand hygiene.
Researchers found that a flu virus can inflame nasal tissue and increase bacterial growth, leading to middle ear infections. The study suggests that the flu virus modifies the immune system's response to certain bacteria, enabling them to infect the middle ear.
Experts warn that dengue vaccines could lead to short-term spikes in disease incidence, but long-term vaccination will reduce overall infections. The issue arises from the natural fluctuations in mosquito populations and the imperfect vaccine protection.
A blend of three monoclonal antibodies has been shown to protect monkeys against a lethal dose of Ebola virus for up to 5 days after infection. This treatment, ZMAPP, was found to be effective in a study published in Nature.
Respiratory infection control measures for Ebola patients are unnecessary and may contribute to public panic, according to a new letter published in The Lancet. Excessive precautions could reinforce the view that some lives are more valuable than others, exacerbating the spread of infection.
Researchers sequenced over 99 Ebola virus genomes from 78 patients in Sierra Leone, finding more than 300 genetic changes that make the 2014 Ebola virus distinct from previous outbreaks. The data provides insights into the outbreak's origin, transmission, and potential targets for diagnostics, vaccines, and therapies.
A new Ebola treatment has shown promise against the Sudan strain of the virus in mice, using synthetic antibodies designed to target a key molecule on the surface of the virus. The treatment is not effective against the Zaire ebolavirus, which is currently devastating West Africa.
A clinical trial has shown that the infection caused by RSV can be effectively reduced after it has started, paving the way for a new treatment. The study found that the oral drug GS-5806 reduced viral load and improved symptoms in healthy adult volunteers infected with RSV.
The rabies virus manipulates axonal transport to reach the brain quickly, with a speed of 8 cm/day, 40% faster than its regular partner NGF.
The 2009 H1N1 outbreak at Washington State University provided valuable data for researchers to study the rapid spread of the virus. A computer model revealed that only a few initial infected individuals sparked the outbreak, with a high transmissibility rate among close-knit student communities.
Researchers at UTMB have developed a treatment effective against the lethal Marburg virus, which has a mortality rate of up to 90%. The treatment protected nonhuman primates from the virus when started three days after infection, showing promise for post-exposure treatment.
Two American missionaries who contracted Ebola virus in West Africa deserve special treatment for their selfless act of caring for infected patients. The author argues that limiting experimental treatment to these two patients is necessary due to the ethical concerns of exploiting vulnerable individuals during a public health outbreak.
The research reveals the viral capsid structure, showing similarities to other viruses, and identifies potential binding sites for modification. The findings may lead to new information on host-virus interactions and the development of custom-made viruses to target parasitic or pathogenic worms.
Researchers discovered that club cells, which normally protect against inhaled microbes, contribute to prolonged inflammation during flu infection. Targeting these cells may help shorten flu symptoms by reducing lung damage.
The article highlights the importance of recognizing Ebola virus infection and isolating patients in hospitals worldwide. Despite concerns about transmission, experts argue that developed countries' effective hospital infection control practices minimize the risk of further spread.
A new experimental chikungunya vaccine performed well in an early clinical trial, eliciting neutralizing antibodies in all participants and providing durable protection for at least 11 months. The vaccine, a virus-like particle (VLP) vaccine, was delivered without an adjuvant and prompted a robust immune response.
A new virus-like particle vaccine has shown promising results in a human trial, generating antibodies that provide long-term protection against chikungunya. The vaccine, composed of non-infectious VLP particles, was well-tolerated and effective across different doses.
Researchers have identified a 52-character biological signal specific to bacterial infection in newborns' DNA, enabling early detection and diagnosis. This breakthrough could lead to the development of a single-drop blood test, limiting antibiotic overuse and tackling drug resistance.
The Ebola virus outbreak in West Africa has claimed over 1,000 lives, with healthcare professionals facing new challenges in capital cities and Nigeria. Dr. Fauci emphasizes the need for sound public health practices, community engagement, and international assistance to defeat the epidemic.
Researchers have discovered how Ebola blocks and disables the body's natural immune response. The protein VP24 disrupts a crucial early step in the virus's path to causing deadly disease. Understanding this mechanism could lead to new treatments for the deadly virus.
A study published in Cell Host & Microbe reveals how the Ebola virus blocks the body's first line of defense against infection. By targeting a specific protein called eVP24, the virus cripples the immune system's ability to respond effectively, allowing it to mass-produce itself and trigger a deadly response.
Researchers at MIT have developed a new technique for studying the hepatitis B virus lifecycle, allowing them to investigate immune responses and drug treatments. The model could help find a cure for the disease by understanding how the virus interacts with liver cells.
The American College of Physicians recommends a full-night polysomnography test for diagnosing obstructive sleep apnea. A computer model predicts that new therapies will make chronic hepatitis C a rare disease by 2036. Physical therapy and corticosteroid injections provide equal relief from shoulder pain and disability, with MPT patien...
Researchers found that childhood coxsackie virus infection depletes cardiac stem cells, impairing the heart's ability to tolerate stress and increasing the risk of heart disease later in life. The study suggests a potential link between early viral infections and long-term cardiovascular health.
Researchers found 101 non-antibiotic drugs with potential to prevent growth of certain bacterial pathogens, including those causing Legionnaires' disease and brucellosis. These drugs interfere with host cell functions to stall intracellular bacterial infections.
A global prevalence study reveals that HCV genotype 1 accounts for over 46% of all cases, followed by genotypes 3 and 2. The study emphasizes the importance of understanding viral genotype to develop new treatments for HCV.
Two new pill-only antiviral drug regimens have shown promise in treating the most difficult-to-cure form of hepatitis C, with high cure rates and minimal side effects. The treatments offer a more effective, safer, and shorter option for patients with cirrhosis or those who have failed existing therapies.
A new drug, AL-8176, has been shown to safely reduce RSV viral load and clinical illness in healthy adult volunteers. The Phase 2 challenge study achieved primary and secondary endpoints of lower viral load and improvements in symptom scores.
Researchers have identified six potential therapeutics for H7N9 influenza by targeting the immune response rather than the virus. The study found that viruses causing severe illness trigger different gene expression signatures compared to milder infections.
A new study determines glycosylation and pH-dependent conformational changes of virus receptor SCARB2 as crucial for EV71 attachment and entry. Researchers found that SCARB2 opens a lipid-transfer tunnel to trigger viral uncoating at acidic conditions, releasing the viral genome into host cells.
Researchers have uncovered how the NF-κB protein complex is activated, a pivotal step in developing cancer, viral infection and autoimmune diseases. The discovery reveals that two additional events are necessary to switch on NF-κB, paving the way for new drug targets.
Researchers found that prior colonization by Streptococcus pneumoniae protected mice from severe disease and pneumonia. The protective effect was linked to the bacterial virulence factor pneumolysin, which reduced inflammation in the lungs.
Researchers found that Wolbachia-infected mosquitoes are more likely to transmit West Nile virus, despite initial expectations that it would block infection. The study suggests that releasing Wolbachia-infected mosquitoes into the wild may increase the risk of West Nile virus transmission.
A new dengue vaccine candidate, CYD-TDV, has shown moderate protection of 56% against the disease in a phase 3 clinical trial. The vaccine demonstrated high efficacy against three out of four dengue viruses and reduced severe disease and hospitalizations by more than half.
Researchers discovered how viruses affect phytoplankton, like Emiliania huxleyi, altering global carbon cycle and marine food chain. Viruses rewire host lipid metabolism, diverting fixed carbon from traditional food web, with implications for ocean ecosystems.
Researchers discovered that trace amounts of HCV RNA in successfully treated patients can be infectious. The study used an animal model to show that blood from these patients could cause HCV infection, which may be hard to detect due to delayed onset of disease.
Scientists have discovered that Lassa virus uses a two-step process to enter cells, involving the transport of the virus to a lysosome and the binding to an interior cell receptor called LAMP1. This finding could lead to new approaches for preventing the disease.
A clinical study found that a certain group of genes and an immune cell ratio can predict tolerance to liver transplants in patients with hepatitis C. This could enable patients to stop taking immunosuppressants after a certain period, reducing the burden of chronic HCV infection.
The review explores how RNA viruses induce Type I and III interferons, which regulate virus replication and host survival. Different types of interferons have distinct antiviral properties, playing a critical role in maintaining an optimum equilibrium between virus replication and host survival.
Norovirus infections contribute substantially to the global burden of acute gastroenteritis, causing both severe and mild cases across all age groups. The virus is highly contagious and can be spread through contaminated food or water and contact with surfaces.
Researchers at the University of Texas Medical Branch have developed a human monoclonal antibody, m102.4, that protects nonhuman primates from Nipah virus disease even five days after infection. This breakthrough could lead to the development of a therapeutic treatment for people infected with the deadly virus.
Scientists at USAMRIID have proposed a set of standards for sequencing viral genomes, providing a common 'language' among researchers. The standards will facilitate the analysis and application of genome sequences across various fields, including diagnostics, vaccine development, and therapeutics.
Researchers at the Icahn School of Medicine at Mount Sinai found that mammals do not use RNAi to fight viruses, contrary to previous studies. Instead, they use microRNAs, which are part of a different defense system based on interferons, signaling proteins made by immune cells.
Research found that equine influenza viruses from the early 2000s can easily infect dog respiratory tracts, while those from the 1960s replicate poorly. The study suggests that canine and human influenza viruses can mix, generating new viruses that could pose a pandemic risk.
A new T cell therapy has been developed to protect immunodeficient patients from infections. The treatment involves transferring a few immune cells, which are then used to fight off specific pathogens, and has shown great potential in clinical trials.
Researchers mapped live poultry markets in China to predict H7N9 spread; dense clusters of markets facilitate emergence and transmission. Maps help target surveillance and contain outbreaks.
Researchers at the University of Texas Medical Branch have identified a new mutation in the chikungunya virus that could lead to more efficient transmission and infection. The mutation, which emerged in the Indian Ocean Basin, has the potential to spread to temperate regions where the Asian tiger mosquito thrives.
A team of researchers has found a potential way to enhance the body's ability to sense and inhibit viral infections by boosting a naturally occurring protein called OASL. This discovery could lead to more effective treatments for viruses ranging from hepatitis C to the flu.
Researchers show that proliferation unlocks expression of Interleukin-10 in NK cells, a protein that moderates the immune system. This helps prevent hyperactivation of CD8 T cells, which can cause damage. The study provides another important role for lymphocyte proliferation and may help design vaccines.
A new study reveals that late-stage sepsis triggers the reactivation of dormant viruses in the body, leading to secondary infections. Researchers found that 43% of sepsis patients had multiple viruses detected in their blood or urine.
A fungal protein has been found to cross the blood-brain barrier, allowing it to infect the brain and cause deadly meningitis. This discovery opens up new avenues for treating brain infections and cancers by targeting the protein or using it as a drug delivery system.
Researchers have discovered a bird flu virus with pandemic potential, closely related to the 1918 Spanish flu. The virus, composed of eight gene segments, can cause flu-like symptoms in ferrets and has the potential to spread efficiently among humans if it acquires key mutations.
A new study from University College London reveals that certain human immune genes, known as APOBEC, can mutate DNA in response to HPV infection, leading to cancer. The research identified specific mutations in the PIK3CA gene, which is a common target for new cancer drugs.
Researchers have unraveled the mechanism of necroptosis, a type of cell death linked to various diseases. Understanding this process enables the development of targeted medications to block or stimulate necroptosis, potentially treating chronic and acute inflammatory and degenerative diseases.
Researchers have discovered how lemurs fight the Cryptosporidium parasite using next-generation sequencing technology. This breakthrough could aid in conservation efforts and develop new methods for detecting and treating the infection.
Researchers tracked real-time virus replication and drug clearance in HCV patients, revealing a lag between liver and blood viral decay. The findings suggest the need for tailored therapy to achieve viral eradication and may inform vaccine development.
The USPSTF recommends screening for hepatitis B virus (HBV) in nonpregnant high-risk adolescents and adults, as well as postnatal immunoprophylaxis to prevent maternal transmission. Studies have shown that these interventions can reduce mortality and hospital readmissions related to heart failure.
A team of scientists has identified a previously unknown form of lymphocyte that protects against intracellular infection, providing important insights into the human immune system. The discovery of these 'precursor cells' could lead to the development of new vaccination strategies to prevent intracellular infections.
A new drug, GS-5806, has been shown to safely reduce viral load and clinical illness in healthy adult volunteers infected with respiratory syncytial virus (RSV). The Phase 2a challenge study achieved primary and secondary endpoints, suggesting potential for clinical trials in naturally infected patients.